Recent Publications by Epimmune Incorporated: |
Measurement of MHC/peptide interactions by gel filtration.
This unit describes a technique for the direct and quantitative... | 6th June, 2008
| Epimmune Incorporated, San Diego, California, USA.
| Curr Protoc Immunol. 2001 May;Chapter 18:Unit 18.3.
DOI Direct Link |
Formulation and Characterization of a Ten-peptide Single-vial Vaccine, EP-2101, Designed to Induce Cytotoxic T-lymphocyte Responses for Cancer Immunotherapy.
Effective vaccines that mediate clinical responses in cancer patients may... | 3rd April, 2008
| Pharmexa-Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA
| Hum Vaccin. 2007 Nov 11;4(3).
|
Rationally engineered therapeutic proteins with reduced immunogenicity.
Chronic administration of protein therapeutics may elicit unacceptable... | 29th April, 2005
| Epimmune, San Diego, CA 92121, USA.
| J Immunol. 2005 Mar 15;174(6):3187-96.
|
Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
Recognition by CD8(+) T lymphocytes (CTL) of epitopes that are derived... | 4th November, 2004
| Epimmune, San Diego, CA 92121, USA.
| J Immunol. 2004 Aug 1;173(3):1941-50.
|
Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).
Experimental carbohydrate-conjugate vaccines composed of the 13 amino acid... | 8th September, 2004
| Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA 92121,
| Vaccine. 2004 Jun 23;22(19):2362-7.
DOI Direct Link |
Design of multi-epitope, analogue-based cancer vaccines.
The current objective of our cancer programme is to develop an effective... | 22nd July, 2004
| Epimmune, Inc., 5820 Nancy Ridge Drive, San Diego, CA 92121, USA.
| Expert Opin Biol Ther. 2003 Sep;3(6):985-93.
DOI Direct Link |
Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
Transgenic mice expressing chimeric human leukocyte antigen (HLA)-B*0702... | 27th September, 2003
| Epimmune Inc., San
| Hum Immunol. 2003 Feb;64(2):211-23.
|
Rationally engineered proteins or antibodies with absent or reduced immunogenicity.
One challenge associated with the clinical use of protein therapeutics... | 27th June, 2003
| Epimmune Incorporated, 5820 Nancy Ridge Drive, San Diego, CA-92121, USA.
| Curr Med Chem. 2002 Dec;9(24):2191-9.
|
Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.
In this review we describe the methods and processes that our group have... | 5th April, 2003
| Epimmune Inc., San Diego, CA 92121, USA.
| Tissue Antigens. 2002 Jun;59(6):443-51.
|
Epitope identification and vaccine design for cancer immunotherapy.
The development of processes for engineering multi-epitope vaccines based... | 18th December, 2002
| Epimmune
| Curr Opin Investig Drugs. 2002 Jan;3(1):132-9.
|
The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity.
Assays to measure the binding capacity of peptides for... | 11th December, 2002
| Epimmune, Inc., San Diego, CA 92121, USA.
| J Immunol. 2002 Nov 1;169(9):5098-108.
|
Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
Cellular immune responses, specifically those mediated by CD8+ cytotoxic... | 26th November, 2002
| Epimmune
| Curr Opin Investig Drugs. 2002 Mar;3(3):374-8.
|
